

**Date: November 14, 2022**

To  
The Listing Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

**Ref: Scrip code: 532669**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that, the meeting of the Board of Directors of the Company held on Monday, November 14, 2022, commenced at 07:00 P.M and concluded at 08.10 P.M.

The Board inter-alia considered and approved the following:

1. Approved the unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2022. **(enclosed herewith)**
2. Took note of the Limited Review Report issued by M/s. Darapaneni & Co., Chartered Accountants, Statutory Auditors of the Company on the unaudited standalone financial results for the quarter and half year ended September 30, 2022. **(enclosed herewith)**
3. To change the name of the Company from Southern Online Bio Technologies Limited to "**Pagidipati Bio Energy Limited**" or "**Pagidipati Renewable Energy Limited**" or such other name as may be approved by the Central Registration Centre, Ministry of Corporate Affairs.

You are requested to take the same on your record.

Thanking you  
**For Southern Online Bio Technologies Limited**

**Rohit Tibrewal**  
**Company Secretary**

Encl: A/a.

**CIN: L72900TG1998PLC030463**

Registered Office: A3, 3rd Floor, Office Block, Samrat Complex, Saifabad, Hyderabad - 500 004. Telangana, India.

Phones: +91-40-23241999, +91-40-44341999, Fax: +91-40-23241444, email: cs@sol.net.in, website: www.sol.net.in

Unit - I : Survey No. 6 & 7, Samsthan Narayanapur (V&M), Yadadri Bhuvanagiri Dist., Telangana, Ph.: +91 8681 287575

Unit - II : Plot No. 45/A, APIIC-SEZ, Atchutapuram (V&M), Visakhapatnam Dist.-531011, Andhra Pradesh, India.

Corporate Office: Flat No. 602, 6th Floor, Swarna Jayanthi Complex, Beside Maitrivanam, Ameerpet, Hyderabad - 500 038.



**DARAPANENI & Co.,**  
**CHARTERED ACCOUNTANTS**

Flat No 1A, Rama Apartments, Plot No 84, Srinagar Colony, Hyderabad - 500073

Tel: 040-23735095, 23736487

E-mail: darapaneni1986@gmail.com

LIMITED REVIEW REPORT


*Limited Review Report on Standalone Unaudited Quarterly Financial Results Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.*

*To the Board of Directors of Southern Online Bio Technologies Ltd*

We have reviewed the accompanying statement of unaudited financial results of M/s SOUTHERN ONLINE BIO TECHNOLOGIES LTD, for the quarter and half year ended 30<sup>th</sup> September 2022, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 14.11.2022

For Darapaneni & Co  
Chartered Accountants  
FRN.000685S



CA. Sree Rama Chandra Murthy Ch.  
Partner  
M.No. 233010  
UDIN: 22233010BDCCBL4337

**M/S. SOUTHERN ONLINE BIO TECHNOLOGIES LIMITED**  
**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED**  
**SEPTEMBER 30<sup>TH</sup>, 2022**

Rs. Lakhs

Particulars		Quarter ended			Half Year Ended		Year Ended	
		30.09.22	30.06.22	30.09.21	30.09.22	30.09.21	31.03.22	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	<b>Revenue from operations</b>							
	Sale of goods/Income from operations		530.34	81.48	56.98	611.82	114.73	248.42
	Other operating revenues							
	<b>Total revenue from operations</b>		<b>530.34</b>	<b>81.48</b>	<b>56.98</b>	<b>611.82</b>	<b>114.73</b>	<b>248.42</b>
II	Other income		3.87	3.10	4.28	6.97	6.38	11.51
III	<b>Total income (I+II)</b>		<b>534.21</b>	<b>84.58</b>	<b>61.27</b>	<b>618.79</b>	<b>121.11</b>	<b>259.93</b>
IV	<b>Expenses</b>							
	a)	Cost of materials consumed	574.76	119.30	148.15	694.06	148.15	148.15
	b)	Purchases of stock- in-trade						
	c)	Changes in inventories of finished goods and work in progress	(151.62)	(119.40)	(148.15)	(271.02)	(148.15)	(148.15)
	d)	Employee benefits expenses	27.35	9.10	10.22	36.46	18.20	35.43
	e)	Finance costs	4.37	0.06	0.06	4.43	0.07	0.08
	f)	Depreciation and amortisation expense	42.32	5.81	5.97	48.13	12.39	21.88
	g)	Other expenses	76.99	61.37	39.28	138.37	76.19	179.57
	<b>Total expenses</b>		<b>574.17</b>	<b>76.25</b>	<b>55.52</b>	<b>650.43</b>	<b>106.86</b>	<b>236.96</b>
V	<b>Profit/(loss) before tax (III-IV)</b>		<b>(39.97)</b>	<b>8.34</b>	<b>5.74</b>	<b>(31.64)</b>	<b>14.26</b>	<b>22.97</b>
VI	<b>Tax expenses:</b>							
	a)	Current tax	-	-	-	-	-	-
	b)	Deferred tax charge/(credit)	-	-	-	-	-	-
	<b>Total Tax Expense</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
VII	<b>Net Profit for the period (V-VI)</b>		<b>(39.97)</b>	<b>8.34</b>	<b>5.74</b>	<b>(31.64)</b>	<b>14.26</b>	<b>22.97</b>
VIII	<b>Other comprehensive income(net of tax)</b>							
	a)	(i) Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans	(1.39)		(1.54)	(1.39)	(1.54)	(0.14)
	b)	Income tax relating to these items that will not be reclassified subsequently to profit or loss	-		-	-	-	-
	<b>Other comprehensive income/(loss) (net of tax)</b>		<b>(1.39)</b>	<b>-</b>	<b>(1.54)</b>	<b>(1.39)</b>	<b>(1.54)</b>	<b>(0.14)</b>

IX	<b>Total comprehensive income/(loss) (VII+VIII)</b>		<b>(41.35)</b>	<b>8.34</b>	<b>4.20</b>	<b>(33.03)</b>	<b>12.71</b>	<b>22.83</b>
X	<b>Paid-up Equity Share Capital (face value ₹ 10 each)</b>		<b>4,500.00</b>	<b>4,500.00</b>	<b>4,500.00</b>	<b>4,500.00</b>	<b>4,500.00</b>	<b>4,500.00</b>
XI	<b>Other Equity</b>		<b>480.57</b>	<b>521.94</b>	<b>452.24</b>	<b>480.57</b>	452	<b>513.60</b>
XII	<b>Net Worth</b>		<b>4,980.57</b>	<b>5,021.94</b>	<b>5,003.48</b>	<b>4,980.57</b>	<b>5,003.48</b>	<b>5,013.60</b>
XIII	<b>Debenture Redemption reserve</b>							
XIV	<b>Capital Redemption reserve</b>							
XV	<b>Securities premium account</b>							
XVI	<b>Paid-up debt Capital</b>							
XVII	Earnings per share (face value ₹ 10 each)							
	a)	Basic (₹)	(0.00)	0.00	0.00	(0.00)	0.00	0.00
	b)	Diluted (₹)	(0.00)	0.00	0.00	(0.00)	0.00	0.00
VIII	<b>Ratios</b>							
	a)	Debt Equity Ratio	0.77	0.72	0.47	0.77	0.47	0.66
	b)	Debt Service Coverage Ratio	-	-	-			
	c)	Interest Service Coverage Ratio	(8.14)	139.85	98.13	(6.14)	209.57	286.00
	d)	Current Ratio	2.12	4.15	12.27	2.12	12.27	12.80
	e)	Long term debt to working capital	4.13	3.37	2.21	4.13	2.21	3.31
	f)	Current liability ratio	0.18	0.09	0.04	2.12	12.27	0.02
	g)	Total debts to total assets	0.47	0.43	0.32	0.47	0.32	0.39
	h)	Bad debts to Account receivable ratio	-	-	-	-	-	-
	i)	Debtors' turnover	1.86	0.27	0.20	2.15	0.40	0.89
	j)	Inventory turnover	1.86	0.27	0.20	0.39	0.31	0.89
	k)	Operating margin (%)	(0.07)	0.06	0.03	2.15	0.40	0.05
	l)	Net profit margin (%)	(0.08)	0.10	0.10	(0.06)	0.07	0.09

**M/S. SOUTHERN ONLINE BIO TECHNOLOGIES LIMITED**  
**UNAUDITED STANDALONE BALANCE SHEET AS AT SEPTEMBER 30<sup>TH</sup>, 2022**

Rs. Lakhs

Particulars	As at 30th Sep,2022	As at 31st Mar, 22
<b>Assets</b>		
<b>(1) Non-current assets</b>		
(a) Property, plant and equipment	5,091.90	5,135.68
(b) Capital Work in Progress	2,718.62	2,183.64
(c) Financial assets		
(i)Loans and advances	-	-
(ii)Investments	-	-
(iii)Other Financial Assets	272.43	276.01
(d) Other non-current assets	64.40	-
<b>Total Non - Current Assets</b>	<b>8,147.35</b>	<b>7,595.33</b>
<b>(2) Current Assets</b>		
(a) Inventories	978.02	430.54
(b) Financial assets		
(i) Trade receivables	284.93	277.85
(ii) Cash and cash equivalents	22.84	52.47
(iii) Loans and advances	3.66	3.42
(c) Other current assets	475.01	325.84
<b>Total Current Assets</b>	<b>1,764.46</b>	<b>1,090.11</b>
<b>Total assets</b>	<b>9,911.81</b>	<b>8,685.44</b>
<b>Equity and liabilities</b>		
<b>(1) Equity</b>		
(a) Share capital	4,500.00	4,500.00
(b) Other equity	480.57	513.60
<b>Total Equity</b>	<b>4,980.57</b>	<b>5,013.60</b>
<b>(2)Share application money, pending allotment</b>		
<b>(3) Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	3,840.83	3,329.98
(ii) Lease Liabilities	-	-
(b) Deferred tax (net)	256.66	256.66
<b>Total Non - Current Liabilities</b>	<b>4,097.49</b>	<b>3,586.64</b>
<b>(4) Current Liabilities</b>		
<b>(a) Financial liabilities</b>		
(i) Short Term Borrowings	500.30	
(ii) Trade payables	245.69	14.85
(A) MSME		-
(B) Others	245.69	14.85
(b) Other current liabilities	87.76	70.35
(c) Provisions		-
<b>Total Current Liabilities</b>	<b>833.75</b>	<b>85.20</b>
<b>Total Liabilities</b>	<b>4,931.24</b>	<b>3,671.84</b>
<b>Total Equity and Liabilities</b>	<b>9,911.81</b>	<b>8,685.44</b>

**M/S. SOUTHERN ONLINE BIO TECHNOLOGIES LIMITED**  
**UNAUDITED STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED**  
**SEPTEMBER 30<sup>TH</sup>, 2022**

Rs. Lakhs

Particulars	Sep 30 <sup>th</sup> , 2022	Sep 30 <sup>th</sup> , 2021	Mar 31 <sup>st</sup> , 2022
<b>A. Cash Flow From Operating Activities :</b>			
Net Profit/(Loss) Before Tax	(31.64)	14.26	22.97
Adjustments for :	-		
Depreciation	48.13	12.39	21.88
OCI relating to Re-measurement of Defined benefit plans	(1.39)	(1.54)	(0.14)
Interest and other Charges on loans	4.43	0.07	0.08
Loss/ (profit) on sale of property, plant and equipment	-		
Operating profit before working capital changes	<b>19.54</b>	<b>25.17</b>	<b>44.80</b>
Adjustments for :			
Trade receivables	(7.08)	(126.37)	(115.46)
Inventory	(547.48)	(148.15)	(216.43)
Short-term loans and advances	(0.25)	12.37	13.14
Non-current Assets	(60.82)	-	(20.59)
Other current assets	(149.17)	(138.40)	(278.45)
Long-term loans and advances	-	276.46	276.46
Trade and other payables	230.84	(298.64)	(305.19)
Other current liabilities	17.41	17.79	13.97
Cash generated from operations	<b>(497.00)</b>	<b>(379.77)</b>	<b>(587.76)</b>
Cash flow before Extraordinary items & Prior period adjustments	<b>(497.00)</b>	<b>(379.77)</b>	<b>(587.76)</b>
Tax paid		-	
Net cash flow from operating activities	<b>(497.00)</b>	<b>(379.77)</b>	<b>(587.76)</b>
<b>B. Cash Flow From Investing Activities :</b>			
Purchase of property, plant and equipment, intangible assets (including capital work in progress)	(539.34)	(250.82)	(1,830.76)
(Purchase)/Sales of Investments		-	34.31
Net cash used in investing activities	<b>(539.34)</b>	<b>(250.82)</b>	<b>(1,796.45)</b>
<b>C. Cash Flow From Financing Activities :</b>			
Proceeds from Unsecured Loans	510.85	1,389.03	2,342.86
Increase / decrease in Short Term liabilities	500.30	-	
Payment of Interest and other Charges on loans	(4.43)	(0.07)	(0.08)
Net cash flow from financing activities	<b>1,006.72</b>	<b>1,388.96</b>	<b>2,342.78</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>	<b>(29.62)</b>	<b>758.36</b>	<b>(41.43)</b>
Opening cash and cash equivalents	52.47	93.90	93.90
<b>Closing cash and cash equivalents</b>	<b>22.84</b>	<b>852.26</b>	<b>52.47</b>

**UNAUDITED SEGMENT INFORMATION FOR THE QUARTER/HALF YEAR ENDED  
30TH SEPTEMBER 2022**

Rs. In lakhs

Particulars	Quarter Ended			Half Year Ended		Year Ended Audited
	30 Sep'22	30 June'22	30 Sep'21	30 Sep'22	30 Sep'21	31 Mar'22
<b>Segment Value of Sales and Services</b>						
Internet Services	58.03	81.48	56.98	139.51	114.73	248.42
Bio Diesel	472.31		-	472.31	-	-
Revenue From Operations	<b>530.34</b>	<b>81.48</b>	<b>56.98</b>	<b>611.82</b>	<b>114.73</b>	<b>248.42</b>
<b>Segment Results (EBITDA)</b>						
Internet Services	(13.73)	14.20	11.71	0.48	26.65	44.73
Bio Diesel	19.69	-	-	19.69	-	-
Total Segment Profit before Interest, Tax, Exceptional item and Depreciation, Amortisation and Depletion	<b>5.96</b>	<b>14.20</b>	<b>11.71</b>	<b>20.17</b>	<b>26.65</b>	<b>44.73</b>
<b>Segment Results (EBIT)</b>						
Internet Services	(19.60)	8.40	5.74	(11.20)	14.26	22.85
Bio Diesel	(16.76)	-	-	(16.76)	-	-
Total Segment Profit before Interest and Tax and Exceptional item	(36.36)	8.40	5.74	(27.96)	14.26	22.85
(i) Finance Costs	4.37	0.06	0.06	4.43	0.07	0.08
(ii) Interest Income	0.76	-	0.06	0.76	0.06	0.20
(iii) Other Un-allocable Income (Net of Expenditure)						
Profit Before Exceptional Item and Tax Exceptional Item (Net of Taxes)	(39.97)	8.34	5.74	(31.64)	14.26	22.97
<b>Profit Before Tax</b>	(39.97)	8.34	5.74	(31.64)	14.26	22.97
(i) Current Tax	-	-		-	-	-
(ii) Deferred Tax	-	-		-	-	-
<b>Profit After Tax</b>	(39.97)	8.34	5.74	(31.64)	14.26	22.97

Particulars	Quarter Ended			Half Year Ended		Year Ended Audited
	30 Sep'22	30 June'22	30 Sep'21	30 Sep'22	30 Sep'21	31 Mar'22
<b>Segmental Assets</b>						
Internet Services	154.95	157.34	368.77	154.95	368.77	284.03
Bio Diesel	9,756.86	9,105.83	7,363.86	9,756.86	7,363.86	8,401.41
<b>Total</b>	<b>9,911.81</b>	<b>9,263.17</b>	<b>7,732.63</b>	<b>9,911.81</b>	<b>7,732.63</b>	<b>8,685.44</b>
<b>Segmental Liabilities</b>						
Internet Services	154.95	157.34	368.77	154.95	368.77	284.03
Bio Diesel	9,756.86	9,105.83	7,363.48	9,756.86	7,363.48	8,401.41
<b>Total</b>	<b>9,911.81</b>	<b>9,263.17</b>	<b>7,732.25</b>	<b>9,911.81</b>	<b>7,732.25</b>	<b>8,685.44</b>



Note:

1. The above Financial results have been reviewed by the audit committee, approved by the Board of Directors in its meeting held on Nov 14, 2022 and reviewed by the Statutory auditors of the Company.
2. The Financial results of the Company have been prepared in accordance with Indian Accounting Standards (IND AS) notified under the Companies (Indian Accounting Standards) Rules 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.
3. Previous period's figure have been re-grouped/re-arranged/re-casted wherever required in conformity with current period's presentation.

For and on behalf of  
Southern Online Biotechnologies Limited

Dr Pagidipati Devaiah  
Chairman and Managing Director  
DIN: 05147621  
Place: Florida  
Date: November 14, 2022